Y-mAbs Therapeutics, Inc. (YMAB)

NASDAQ: YMAB · IEX Real-Time Price · USD
-0.24 (-1.59%)
Jul 1, 2022 1:00 PM EDT - Market open

Company Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.

It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors.

The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.

Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Y-mAbs Therapeutics, Inc.
Country United States
Founded 2015
IPO Date Sep 21, 2018
Industry Biotechnology
Sector Health Care
Employees 148

Contact Details

230 Park Avenue
New York, NY 10169
United States
Phone 646 885 8505
Website ymabs.com

Stock Details

Ticker Symbol YMAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001722964
CUSIP Number 984241109
ISIN Number US9842411095
Employer ID 47-4619612
SIC Code 2834

Key Executives

Name Position
Thomas Gad Founder, Interim Chief Executive Officer, President, Head of Business Development and Strategy and Director
Bo Kruse Executive Vice President, Secretary, Treasurer and Chief Financial Officer
Dr. Steen Lisby M.D., M.Sc. Senior Vice President and Chief Scientific Officer
Dr. Vignesh Rajah M.B.A., MBBS Senior Vice President and Chief Medical Officer
Joris Wiel Jan Wilms Senior Vice President and Chief Operating Officer
Dr. Torben Lund-Hansen M.Sc., Ph.D. Senior Vice President and Head of Technical Operations
Sue Smith Senior Vice President and Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 13, 2022 8-K Current report
Jun 2, 2022 8-K Current report
May 31, 2022 8-K Current report
May 26, 2022 8-K Current report
May 19, 2022 8-K Current report
May 19, 2022 4 Statement of changes in beneficial ownership of securities
May 9, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 9, 2022 8-K Current report
Apr 29, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022 DEF 14A Other definitive proxy statements